News
BMS’ GvHD therapy granted breakthrough status in US
Bristol-Myers Squibb has been awarded Breakthrough Therapy Designation in the US for Orencia (abatacept) for the prevention of moderate-to-severe acute graft-verses-host disease (GvHD) in...
French biotech raises $53m to advance clinical pipeline
French biotech, ImCheck Therapeutics, has closed a $53 million Series B financing round to advance its clinical pipeline of novel gamma delta T-cell-focussed antibodies...
FDA approves Tecentriq combo for NSCLC
Tecentriq has chalked up another approved indication after the FDA rubber-stamped the drug in combination with chemotherapy for first-line treatment of metastatic non-squamous non-small...
